Therapy of HIV Infection: Current Approaches and Prospects

Prokofjeva, M. M.; Kochetkov, Sergey N.; Prassolov, Vladimir

doi:10.32607/20758251-2016-8-4-23-32

Cited by 23 publications

(19 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antiretroviral therapy (ART) is used to suppress HIV infection. It comprises pharmacological drug classes including nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), fusion inhibitors, and chemokine receptor antagonists [10,11]. The WHO 2013 ART guidelines recommended a fixed-dose, single-tablet regimen containing two NRTIs [tenofovir disoproxil fumarate (TDF) + lamivudine (3TC)] plus one NNRTI [efavirenz (EFV)] (TLE600 STR) as the preferred first-line regimen for ART-na€ ıve adults and adolescents in low-and middle-income countries (LMICs) such as India [12].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in Pune, India

Dravid

Betha²,

Sharma³

et al. 2020

HIV Medicine

View full text Add to dashboard Cite

Objectives As per National AIDS Control Organization (NACO) estimates, there are 2.1 million people living with HIV (PWH) in India, of whom 1.2 million are on first‐line antiretroviral therapy (ART). This study explored the use of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg + lamivudine 300 mg + efavirenz 400 mg (TLE400 STR) as a first‐line switch strategy in PWH in Pune, India. Methods This retrospective cohort study was conducted in private sector ART clinics in three tertiary‐level hospitals in Pune, India. PWH > 12 years of age (n = 502) who initiated first‐line ART (predominantly TLE600 STR), completed ≥ 6 months of follow‐up and achieved virological suppression [plasma viral load (VL) < 1000 HIV‐1 RNA copies/mL] were identified and switched to TLE400 STR. The virological and immunological efficacy of TLE400 STR at 6 and 12 months of follow‐up were noted. Grade 3/4 adverse events (especially efavirenz‐related neuropsychiatric adverse events) leading to regimen discontinuation were also noted. Results Of 502 PWH who switched to TLE400 STR, complete virological suppression (VL < 20 copies/mL) was maintained in more than 97% of patients at follow‐up. TLE400 STR was successful in maintaining CD4 counts within the range observed at the start of the regimen. Grade 3/4 adverse events leading to TLE400 STR discontinuation were seen in 11 (2.2%) patients. Virological failure (VL > 1000 copies/mL) and treatment regimen failure were seen in six (1.2%) and 49 (9.8%) subjects, respectively. Conclusions TLE400 STR exhibits excellent efficacy and safety as a switch strategy and should be introduced in the Indian National ART Program, especially for PWH who are virologically suppressed on TLE600 STR.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in Pune, India

Dravid

Betha²,

Sharma³

et al. 2020

HIV Medicine

View full text Add to dashboard Cite

show abstract

“…Author details 1 Nanjing University of Aeronautics and Astronautics, College of Economics and Management, Nanjing, Jiangshu, China, 211106. 2 Shanghai Public Health Clinical Center, Fudan University Shanghai, China, 201508.…”

Section: Ethics Approval and Consent To Participatementioning

confidence: 99%

“…Acquired immunode ciency syndrome (AIDS), caused by the human immunode ciency virus (HIV), is one of the most serious infectious diseases in the world [1], with no cure or effective vaccine so far. Highly active antiretroviral therapy (ART), developed in 1996, is still the only effective method to inhibit HIV replication.…”

Section: Introductionmentioning

confidence: 99%

Adherence predictor variables in AIDS patients: An empirical study using the data mining-based RFM model

Li¹,

Wang²,

Shen³

2020

Preprint

View full text Add to dashboard Cite

Background Highly active antiretroviral therapy (ART) is still the only effective method to stop the disease progression in acquired immunodeficiency syndrome (AIDS) patients. However, poor adherence to the therapy makes it ineffective. In this work, we construct an adherence prediction model of AIDS patients using the classical recency, frequency and monetary value (RFM) model in the data mining-based customer relationship management model to obtain adherence predictor variables. Methods We cleaned 257305 diagnostic data elements of AIDS outpatients in Shanghai from August 2009 to December 2019 to obtain 16440 elements. We tested the RFM and RFm (R: recent consultation month, F: consultation frequency, M/m: total/average medical costs per visit) models, three clustering methods (K-means, Kohonen and two-step clustering) and four decision algorithms (C5.0, the classification and regression tree, Chi-square Automatic Interaction Detector and Quick, Unbiased, Efficient, Statistical Tree) to select the optimal combination. The optimal model and clustering analysis were used to divide the patients into two groups (good and poor adherence), then the optimal decision algorithm was used to construct the prediction model of adherence and obtain its predictor variables. Results The results revealed that the RFm model, K-means clustering analysis and C5.0 algorithm were optimal. After three rounds of k-means clustering analysis, the optimal RFm clustering model quality was 0.8, 10614 elements were obtained, including 9803 and 811 from patients with good or poor adherence, respectively, and five types of patients were identified. The prediction model had an accuracy of 100% with the recent consultation month as an important adherence predictor variable. Conclusions This work presented a prediction model for medication adherence in AIDS patients at the designated AIDS center in Shanghai, using the RFm model and the k-means and C5.0 algorithms. The model can be expanded to include patients from other centers in China and worldwide.

show abstract

“…Drugs that directly inhibit virus replication have become mainstays in the treatment of chronic viral infections such as HIV/AIDS, 1 hepatitis C virus (HCV), 2 hepatitis B virus, herpesvirus and acute infections such as influenza. RNA viruses such as HIV-1 and HCV possess ideal targets for virus inhibition such as RNA-dependent RNA polymerase and protease.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis

Pedersen

Kim

Liu

et al. 2017

Journal of Feline Medicine and Surgery

199

249

View full text Add to dashboard Cite

ObjectivesThe safety and efficacy of the 3C-like protease inhibitor GC376 was tested on a cohort of client-owned cats with various forms of feline infectious peritonitis (FIP).MethodsTwenty cats from 3.3–82 months of age (mean 10.4 months) with various forms of FIP were accepted into a field trial. Fourteen cats presented with wet or dry-to-wet FIP and six cats presented with dry FIP. GC376 was administered subcutaneously every 12 h at a dose of 15 mg/kg. Cats with neurologic signs were excluded from the study.ResultsNineteen of 20 cats treated with GC376 regained outward health within 2 weeks of initial treatment. However, disease signs recurred 1–7 weeks after primary treatment and relapses and new cases were ultimately treated for a minimum of 12 weeks. Relapses no longer responsive to treatment occurred in 13 of these 19 cats within 1–7 weeks of initial or repeat treatment(s). Severe neurologic disease occurred in 8/13 cats that failed treatment and five cats had recurrences of abdominal lesions. At the time of writing, seven cats were in disease remission. Five kittens aged 3.3–4.4 months with wet FIP were treated for 12 weeks and have been in disease remission after stopping treatment and at the time of writing for 5–14 months (mean 11.2 months). A sixth kitten was in remission for 10 weeks after 12 weeks of treatment, relapsed and is responding to a second round of GC376. The seventh was a 6.8-year-old cat with only mesenteric lymph node involvement that went into remission after three relapses that required progressively longer repeat treatments over a 10 month period. Side effects of treatment included transient stinging upon injection and occasional foci of subcutaneous fibrosis and hair loss. There was retarded development and abnormal eruption of permanent teeth in cats treated before 16–18 weeks of age.Conclusions and relevanceGC376 showed promise in treating cats with certain presentations of FIP and has opened the door to targeted antiviral drug therapy.

show abstract

Therapy of HIV Infection: Current Approaches and Prospects

Cited by 23 publications

References 72 publications

Adherence predictor variables in AIDS patients: An empirical study using the data mining-based RFM model

Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis

Contact Info

Product

Resources

About